Evolution of the Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (<scp>FPBCC</scp>): A Statewide Initiative Toward Improving Transplant Outcomes

There was a substantial improvement in the 1-year survival of allogeneic transplant recipients treated in FPBCC centers, achieved after the initiation of consortium activities. Within a 3-year period, consortium centers, which had a lower starting point, reached 1-year survival comparable to that of other small and large centers. A significant improvement in survival, although a lesser percentage of change, was seen in other programs of similar size across the country, but not in larger programs. We consider that the magnitude of improvement in survival (12% points or 4% per year), which was not seen among other programs, attests to the effectiveness of consortium activities. A blueprint for improvement in outcomes established by the FPBCC can be shared with other programs around the world that strive to improve posttransplant survival.

Authors

Institutions

Publication Details

Journal
Pediatric Transplantation
Published
2025-03-06
DOI
https://doi.org/10.1111/petr.70059
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evolution of the Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC): A Statewide Initiative Toward Improving Transplant Outcomes

Warren Alperstein, Deepak Chellapandian, David Crawford, Reema Kashif et al.
Pediatric Transplantation
Hematopoietic Stem Cell Transplantation
article

Evolution of the Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC): A Statewide Initiative Toward Improving Transplant Outcomes

Warren Alperstein, Deepak Chellapandian, David Crawford, Reema Kashif, Jordan Milner, Mansi Dalal, Edward Ziga, John A. Ligon, Michael Joyce, Paul Castillo, Jorge Galvez‐Silva, Natalie Booth, Minelys M. Alicea Marrero, Biljana Horn, Jessica Peters, Jin‐Ju Lee
article en

Abstract

There was a substantial improvement in the 1-year survival of allogeneic transplant recipients treated in FPBCC centers, achieved after the initiation of consortium activities. Within a 3-year period, consortium centers, which had a lower starting point, reached 1-year survival comparable to that of other small and large centers. A significant improvement in survival, although a lesser percentage of change, was seen in other programs of similar size across the country, but not in larger programs. We consider that the magnitude of improvement in survival (12% points or 4% per year), which was not seen among other programs, attests to the effectiveness of consortium activities. A blueprint for improvement in outcomes established by the FPBCC can be shared with other programs around the world that strive to improve posttransplant survival.

Pediatric TransplantationVol. 29(3)
University of Miami (US), University of Florida (US), Miami Children's Hospital (US), Wolfson Children's Hospital (US)
Partnerships for the goals
Openalex Percentile: Top 94%
Hematopoietic Stem Cell Transplantation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.